



## **2021 AASLD Abstract Categories and Descriptors (The Liver Meeting®)**

### **Acute Liver Failure and Artificial Liver Support**

AO1 Acute Liver Failure and Artificial Liver Support

### **Advanced Practice Providers (NP, PA, RN, PharmD, etc.)**

BO1 Behavioral and Quality Issues

BO2 Practice Issues

### **Alcohol-associated Liver Diseases: Clinical and Experimental**

CO1 Alcohol-associated Liver Diseases: Clinical and Experimental

### **Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis**

DO1 Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts

DO2 Cholangiocyte Biology

DO3 Experimental Cholestasis

### **Cell and Molecular Biology**

EO1 Cell Structure and Function

EO2 Signal Transduction and Nuclear Receptors

EO3 Gene Expression and Therapy

EO4 Stem Cell Biology

### **Genomics and Precision Medicine**

FO1 Genomics and Precision Medicine

### **Gut Liver Axis and Microbiome**

GO1 Gut Liver Axis and Microbiome

### **Health Services and Public Health Research**

HO1 Health Care Delivery/Access/Quality/Equity

HO2 Cost-Effectiveness and Economics of Care

HO3 Patient Centered Outcomes Research

### **Hepatitis B**

IO1 Virology, Pathogenesis, and Immunology

IO2 Diagnostics and Biomarkers

IO3 Epidemiology, Prevention, Natural History

IO4 Therapeutics: Approved Agents

IO5 Therapeutics: New Agents

### **Hepatitis C**

JO1 Virology, Pathogenesis, and Immunology

JO2 Diagnostics, Epidemiology, and Natural History

JO3 Therapeutics: New Agents

JO4 Therapies: General Populations

JO5 Therapies: Unique Populations

### **Hepatitis: Other Infections**

KO1 Hepatitis: Other Infections



### **Hepatobiliary Neoplasia**

- LO1 Experimental Hepatocarcinogenesis
- LO2 Diagnostics and Liver Imaging
- LO3 Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

### **Hepatotoxicity**

- MO1 Pathogenesis and Mechanisms
- MO2 Drug Metabolism, Toxicity and Therapeutics
- MO3 Predictors of Drug Toxicity

### **Human Cholestatic and Autoimmune Liver Diseases**

- NO1 PBC/PSC and Other Cholestatic Disease
- NO2 Autoimmune Liver Disease

### **Inflammation and Immunobiology**

- OO1 Animal Models
- OO2 Innate Immunity
- OO3 Adaptive Immunity
- OO4 Mechanisms of Injury

### **Liver Fibrogenesis and Non-Parenchymal Cell Biology**

- PO1 Basic Fibrosis Research and Stellate Cell Biology
- PO2 Imaging and Noninvasive Markers of Liver Disease
- PO3 Clinical and Translational Fibrosis Research

### **Liver Transplantation and Liver Surgery**

- QO1 Cellular Immunobiology, Preservation, and Cell Transplantation
- QO2 Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
- QO3 Immunosuppression, Outcomes, Complications
- QO4 Viral Hepatitis

### **Metabolic and Genetic Disease**

- RO1 Hemochromatosis, Wilson Disease, and  $\alpha$ -1 Antitrypsin Deficiency

### **NAFLD and NASH**

- SO1 Experimental: Basic
- SO2 Experimental: Clinical
- SO3 Epidemiology and Natural History, Prevention and Outcomes
- SO4 Diagnostics and Biomarkers
- SO5 Therapeutics: Pharmacologic and Other

### **Pediatric Hepatology**

- TO1 Pediatric Liver Disease – Basic Science
- TO2 Biliary Atresia and Cholestasis
- TO3 Viral and Autoimmune Hepatitis
- TO4 Metabolic and Genetic Diseases
- TO5 Pediatric Liver Transplantation



**Portal Hypertension and Other Complications of Cirrhosis**

- UO1 Experimental
- UO2 Ascites, Renal Dysfunction, and Hepatorenal Syndrome
- UO3 Varices and Bleeding
- UO4 Encephalopathy and Other Complications
- UO5 Infections and Acute on Chronic Liver Failure

**Training and Education (Career Development)**

- VO1 Training and Education (Career Development)

**COVID-19 and the Liver**

1. Basic
2. Clinical/Translational
3. Transplant
4. Health Services